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IMs, but not AMs, have the capacity to prevent airway allergy induced 















































Phenotypic and functional comparison of IMs, AMs, and lung DCs. 
(A) The percentage of IMs (F4/80+CD11c–), AMs (F4/80+CD11c+), and 
DCs (F4/80–CD11c+) in whole lung from BALB/c mice was determined 
by flow cytometry. IMs, AMs, and DCs were also stained for MHC II 
and CD68. (B) The percentage of F4/80+CD11c–, F4/80+CD11c+, and 
F4/80–CD11c+ cells in BALF from BALB/c mice. (C–E) Lung cryo-
sections were double stained for CD11c (blue) and F4/80 (red). IMs 
(F4/80+CD11c–) are stained red, DCs (F4/80–CD11c+) are stained blue, 
and AMs (F4/80+CD11c+) are double stained. (C) Representative pho-
tographs showing some IMs, AMs, and DCs (original magnification, 
×100). The average number of IMs and AMs per field was calculated. 
(D) Image of IMs in the vicinity of DCs (original magnification, ×100). 
(E) Photographs at higher magnification showing IMs, AMs, interstitial 
F4/80+CD11c+ macrophages, and DCs (original magnification, ×200). 
(F and G) Alternatively, F4/80 was stained pink rather than red. (F) 
Representative photographs showing some IMs (pink), DCs (blue), 
and AMs (purple) (original magnification, ×100). (G) Photographs at 
higher magnification (original magnification, ×200). (H) FACS-sorted 
APCs were cocultured with FITC-labeled dextran in the absence or 
presence of sodium azide. After 45 minutes, the uptake of fluorescent 
dextran was determined by flow cytometry. (I) FACS-sorted APCs 
(1 × 104 or 4 × 104 cells/well) were loaded with the DO11.10 OVA 
peptide and cocultured for 3 days with naive DO11.10 CD4+ T cells. 
DO11.10 T cell proliferation was assessed by [3H]thymidine uptake in 
a 16-hour pulse. *P < 0.05 (H and I).
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IMs are able to suppress the induction of airway allergy by OVA-
pulsed, LPS-stimulated DCs. (A–G) Naive BALB/c mice were injected 
i.t. with PBS-BMDCs, OVALPS-BMDCs, OVALPS-BMDCs/AMs, OVALPS-
BMDCs/IMs, OVALPS-BMDCsIMmemb, or OVALPS-BMDCs/IMs/AMs. 
From day 10 to day 14, mice were exposed to OVA aerosols. Twenty-
four hours after the last challenge, the severity of airway allergy was 
evaluated. (A) BALF was subjected to total and differential cell counts. 
(B and C) Lung sections were stained with either H&E (B) or PAS 
(C) (original magnification, ×100). (D) Levels of OVA-specific IgE were 
measured in serum samples by ELISA. OVA-specific IgE levels are 
expressed as AU. (E and F) MLN cells were restimulated in vitro for 
3 days with 50 μg/ml OVA. (E) The proliferation was measured as 
[3H]thymidine incorporation during the last 16 hours. (F) Culture super-
natants were assayed for IL-4, IFN-γ, IL-5, and IL-13 by ELISA. (G) 
AHR to various doses of methacholine was assessed by invasive mea-
surement of dynamic resistance. *P < 0.05 versus OVALPS-BMDCs and 
OVALPS-BMDCs/AMs (A and D–G).
Figure 
IMs can inhibit DC-mediated priming of Th2 cells. (A and B) Naive BALB/c mice were injected i.v. with 107 CFSE-labeled DO11.10 T cells (day –1). 
Twenty-four hours later (day 0), mice received an i.t. administration of PBS-BMDCs, OVALPS-BMDCs, OVALPS-BMDCs/AMs, OVALPS-BMDCs/
IMs, OVALPS-BMDCsIMmemb, or OVALPS-BMDCs/IMs/AMs. On day 3, MLNs were collected. (A) Proliferation of CFSE-labeled OVA-specific T cells 
was measured by flow cytometry. DI, division index; Max, maximum. (B) MLN cells were restimulated in vitro for 3 days with 25 μg/ml OVA, and 
supernatants were assayed for IL-4 by ELISA. *P < 0.05 versus OVALPS-BMDCs and OVALPS-BMDCs/AMs.
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IMs have the capacity to attenuate LPS-induced maturation and migration of antigen-loaded DCs. (A) Lung DCs (106 cells) from BALB/c mice 
were stimulated for 16 hours with OVALPS in the presence or absence of AMs (2 × 106 cells) or IMs (1 × 106 cells). DCs were then assayed for 
expression of CD40, CD80, CD86, and MHC II by FACS. Freshly isolated lung DCs served as control (Ctrl). MFIs are shown. (B) Lung DCs were 
placed in fresh medium or in the supernatant (sn) of OVALPS-stimulated IMs or AMs. DCs were then treated with OVALPS for 2 hours, incubated 
with Brefeldin A for an additional 5 hours, and finally stained for IL-12p40. The percentage of IL-12–positive cells was measured by FACS. (C 
and D) Lung DCs (2 × 104 cells) were stimulated for 16 hours with OVALPS in the presence or absence of AMs (4 × 104 cells) or IMs (2 × 104 
cells). APCs were then cocultured for 72 hours with 2 × 105 DO11.10 CD4+ T cells. Unpulsed DCs were used as controls. (C) DO11.10 T cell 
proliferation was measured. (D) IL-4 and IL-5 were measured in the supernatants (ELISA). (E) CFSE-labeled OVALPS-DCs, OVALPS-DCs/AMs, 
or OVALPS-DCs/IMs were injected in the trachea of naive mice. Control mice received PBS. Twenty-four hours later, MLNs were digested and 
stained for F4/80 and CD11c. The percentages of migrating DCs (CFSE+F4/80–CD11c+) among total MLN cells were determined by FACS. The 
total numbers of migrating DCs were calculated. *P < 0.05 (A and C–E).
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IL-10 secretion by IMs is required for functional paralysis of LPS-stimu-
lated DCs. (A) IMs, AMs, and lung DCs were stimulated with OVALPS. 
Sixteen hours later, supernatants were assayed for IL-10 and TGF-β. 
*P < 0.05 versus AMs and DCs. †P < 0.05 versus unstimulated IMs. 
(B) Lung DCs were stimulated for 16 hours with OVALPS in the pres-
ence or absence of WT or Il10–/– IMs. DCs were assayed for expres-
sion of CD40, CD80, CD86, and MHC II by FACS. MFIs are shown. 
Ctrl, freshly isolated DCs. *P < 0.05 versus Ctrl and OVALPS plus IMs. 
(C) Lung DCs were placed in fresh medium or in the supernatant of 
OVALPS-stimulated WT or Il10–/– IMs. DCs were treated and stained 
as in Figure 4B. The percentage and MFI of IL-12–positive cells were 
measured by FACS. (D) CFSE-labeled OVALPS-DCs, OVALPS-DCs/
IMs, and OVALPS-DCs/Il10–/– IMs were injected i.t. to recipients. Con-
trol mice received PBS. Twenty-four hours later, the percentages of 
migrating DCs (CFSE+F4/80–CD11c+) among total MLN cells were 
determined by FACS. (E and F) Mice were injected with CFSE-labeled 
OT-II T cells. Twenty-four hours later, mice received PBS-BMDCs, 
OVALPS-BMDCs, OVALPS-BMDCs/IMs, or OVALPS-BMDCs/Il10–/– IMs. 
Three days later, proliferation of CFSE-labeled OVA-specific T cells in 
MLNs was measured by FACS (E). Alternatively, MLN cells were res-
timulated with OVA, and supernatants were assayed for IL-4 (F). (G) 
Mice received PBS-BMDCs, OVALPS-BMDCs, OVALPS-BMDCs/IMs, or 
OVALPS-BMDCs/IL-10–/– IMs. From days 10 to 14, mice were exposed 
to OVA aerosols. On day 15, BALF cell numbers were determined. 
*P < 0.05 versus PBS-BMDCs and OVALPS-BMDCs/IMs (F and G).
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Specific depletion of IMs by i.p. injection of anti-F4/80 antibod-
ies.  (A–C) Naive BALB/c mice were injected i.p. on 3 consecu-
tive days with 250 μg of depleting anti-F4/80 or control iso-
type antibodies. (A and B) On day 4, lungs were digested and 
stained for F4/80 and CD11c. (A) Percentages of lung DCs 
(F4/80–CD11c+; lower-right quadrant), AMs (F4/80+CD11c+; 
upper-right), and IMs (F4/80+CD11c–; upper-left) among living 
cells. (B) Percentages of lung DCs, AMs, and IMs among dead 
and living cells (all events were considered; left panels). FACS 
analysis of the forward scatter (FSC) and side scatter (SSC) 
is provided to show the specific effects of depleting anti-F4/80 
antibodies on IM morphology (middle panels). Cells were incu-
bated with DAPI in order to stain dead cells (right panels). Only 
IMs were dead (DAPI-positive) following anti-F4/80 treatment. 
(C) Lung cryosections from isotype antibody– and anti-F4/80 
antibody–treated mice were stained for the pan-macrophage 
marker CD68 (original magnification, ×100).
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Figure 
IMs prevent LPS-triggered Th2 responses to innocuous inhaled antigens. (A–G) Naive BALB/c mice were injected i.p. daily from day 1 to 3 with 
depleting anti-F4/80 or control isotype antibodies. (A–C) On day 2, mice received an i.t. injection of OVALPS. (A and B) On day 6, MLN cells 
were restimulated for 3 days with 25 μg/ml OVA. The proliferation was measured (A), and culture supernatants were assayed for IL-4 and IL-5 
by ELISA (B). (C) From day 11 to 14, mice were challenged intranasally with 25 μg OVA (grade V; Sigma-Aldrich) in 50 μl PBS. On day 15, 
BALF was subjected to differential cell counts. (D) On day 2, IM-depleted and control mice were injected i.t. with 100 μg FITC-OVA (rather than 
unlabeled OVA) and 10 ng LPS. On day 3, MLNs were analyzed by flow cytometry for the presence of OVA-loaded DCs (FITC+F4/80–CD11c+). 
Percentages (left) and total numbers (right) of migrating DCs are shown. (E) On day 4, the percentages of T (CD3ε+, CD4+, or CD8α+ cells) and 
B (CD19+ cells) cells in MLNs were measured by flow cytometry. (F and G) On day 4, B and T cells were isolated from MLNs and stimulated 
ex vivo with agonist anti-CD40 antibodies or anti-CD3 and anti-CD28 antibodies, respectively. Control cells were left unstimulated. B cell (F) 
and T cell (G) proliferation was measured as [3H]thymidine incorporation during the last 16 hours of a 2-day culture. *P < 0.05 versus results 
obtained with isotype control antibodies (A–D).
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